Myristyl nicotinateAlternative Names: Nia-114; Niacin prodrug - Niadyne Pharma; Tetradecyl nicotinate
Latest Information Update: 19 Jan 2016
At a glance
- Originator Niadyne
- Developer Niadyne; University of Arizona
- Class Antineoplastics; Nicotinic-acids; Skin disorder therapies
- Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Skin cancer
- Clinical Phase Unknown Plaque psoriasis